ATE499103T1 - Verfahren zur behandlung von arzneimittelinduzierter peripherer neuropathie und verwandten krankheitsformen - Google Patents
Verfahren zur behandlung von arzneimittelinduzierter peripherer neuropathie und verwandten krankheitsformenInfo
- Publication number
- ATE499103T1 ATE499103T1 AT07075011T AT07075011T ATE499103T1 AT E499103 T1 ATE499103 T1 AT E499103T1 AT 07075011 T AT07075011 T AT 07075011T AT 07075011 T AT07075011 T AT 07075011T AT E499103 T1 ATE499103 T1 AT E499103T1
- Authority
- AT
- Austria
- Prior art keywords
- peripheral neuropathy
- related media
- treating drug
- induced peripheral
- compound
- Prior art date
Links
- 208000033808 peripheral neuropathy Diseases 0.000 title abstract 2
- 108010025020 Nerve Growth Factor Proteins 0.000 abstract 3
- 230000008760 nerve sprouting Effects 0.000 abstract 3
- 102000015336 Nerve Growth Factor Human genes 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229940053128 nerve growth factor Drugs 0.000 abstract 2
- 210000000578 peripheral nerve Anatomy 0.000 abstract 2
- 208000004454 Hyperalgesia Diseases 0.000 abstract 1
- 208000035154 Hyperesthesia Diseases 0.000 abstract 1
- 102000007072 Nerve Growth Factors Human genes 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000003900 neurotrophic factor Substances 0.000 abstract 1
- 230000003040 nociceptive effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/28—Oxygen atom
- C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Magnetic Treatment Devices (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21684400P | 2000-07-07 | 2000-07-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE499103T1 true ATE499103T1 (de) | 2011-03-15 |
Family
ID=22808722
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT07075011T ATE499103T1 (de) | 2000-07-07 | 2001-07-06 | Verfahren zur behandlung von arzneimittelinduzierter peripherer neuropathie und verwandten krankheitsformen |
| AT01950964T ATE495177T1 (de) | 2000-07-07 | 2001-07-06 | Verfahren zur behandlung von arzneimittelinduzierter peripherer neuropathie und verwandten krankheitsformen |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01950964T ATE495177T1 (de) | 2000-07-07 | 2001-07-06 | Verfahren zur behandlung von arzneimittelinduzierter peripherer neuropathie und verwandten krankheitsformen |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US6630478B2 (de) |
| EP (3) | EP1334103B1 (de) |
| AT (2) | ATE499103T1 (de) |
| AU (2) | AU2001273212A1 (de) |
| DE (2) | DE60143850D1 (de) |
| DK (2) | DK1334103T3 (de) |
| ES (2) | ES2385931T3 (de) |
| WO (2) | WO2002004448A2 (de) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996003125A1 (en) * | 1994-07-25 | 1996-02-08 | Glasky Alvin J | Carbon monoxide dependent guanylyl cyclase modifiers |
| US20020156277A1 (en) * | 2001-04-20 | 2002-10-24 | Fick David B. | Synthesis and methods of use of purine analogues and derivatives |
| US6759427B2 (en) * | 2001-04-20 | 2004-07-06 | Spectrum Pharmaceuticals, Inc. | Synthesis and methods of use of tetrahydroindolone analogues and derivatives |
| US20030055249A1 (en) * | 2001-07-17 | 2003-03-20 | Fick David B. | Synthesis and methods of use of pyrimidine analogues and derivatives |
| US7410981B2 (en) * | 2002-06-14 | 2008-08-12 | Takeda Pharmaceutical Company Limited | Prodrugs of imidazole derivatives, for use as proton pump inhibitors in the treatment of e.g. peptic ulcers |
| EP1715921B1 (de) * | 2003-09-25 | 2013-04-24 | Abraxis BioScience, Inc. | Tetrahydroindolon-derivate zur Behandlung von neurologischen Erkrankungen |
| WO2005048926A2 (en) * | 2003-11-13 | 2005-06-02 | The General Hospital Corporation | Methods for treating pain |
| US8012964B2 (en) * | 2004-03-26 | 2011-09-06 | Dainippon Sumitomo Pharma Co., Ltd. | 9-substituted 8-oxoadenine compound |
| US8916550B2 (en) | 2005-05-09 | 2014-12-23 | Hydra Biosciences, Inc. | Compounds for modulating TRPV3 function |
| EP2392328A1 (de) * | 2005-05-09 | 2011-12-07 | Hydra Biosciences, Inc. | Verbindungen zur Modulierung der TRPV3-Funktion |
| TW200801003A (en) * | 2005-09-16 | 2008-01-01 | Astrazeneca Ab | Novel compounds |
| EP1976495A2 (de) * | 2006-01-06 | 2008-10-08 | Aarhus Universitet | Auf den serotonin-transporter wirkende verbindungen |
| US8138172B2 (en) * | 2006-07-05 | 2012-03-20 | Astrazeneca Ab | 8-oxoadenine derivatives acting as modulators of TLR7 |
| EP2046335A2 (de) * | 2006-08-01 | 2009-04-15 | Spectrum Pharmaceuticals, Inc. | Verfahren und pharmazeutische präparate als beitrag zur behandlung chemotherapie-induzierter nervenleiden |
| TW200831105A (en) * | 2006-12-14 | 2008-08-01 | Astrazeneca Ab | Novel compounds |
| ES2373616T3 (es) * | 2007-03-19 | 2012-02-07 | Astrazeneca Ab | Compuestos de 8-oxo-adenina 9 sustituidos como moduladores del receptor de tipo toll (tlr7). |
| ES2457316T3 (es) * | 2007-03-19 | 2014-04-25 | Astrazeneca Ab | Compuestos 8-oxo-adenina 9 sustituidos como moduladores del receptor similares a toll (TLR7) |
| JPWO2008114819A1 (ja) * | 2007-03-20 | 2010-07-08 | 大日本住友製薬株式会社 | 新規アデニン化合物 |
| AR065784A1 (es) * | 2007-03-20 | 2009-07-01 | Dainippon Sumitomo Pharma Co | Derivados de 8-oxo adenina,medicamentos que los contienen y usos como agentes terapeuticos para enfermedades alergicas, antivirales o antibacterianas. |
| HRP20120895T1 (hr) * | 2007-05-08 | 2012-11-30 | Astrazeneca Ab | Imidazokinolini sa imuno-modulacijskim svojstvima |
| US8821431B2 (en) * | 2007-09-07 | 2014-09-02 | Beta O2 Technologies Ltd. | Air gap for supporting cells |
| WO2009049157A1 (en) * | 2007-10-11 | 2009-04-16 | Smithkline Beecham Corporation | Novel seh inhibitors and their use |
| EP2219648A4 (de) * | 2007-11-09 | 2010-11-03 | Cenomed Biosciences Llc | Behandlung von postraumatischem stress mit tetrahydroindolon-arylpiperazin-verbindungen |
| PE20091156A1 (es) | 2007-12-17 | 2009-09-03 | Astrazeneca Ab | Sales de (3-{[[3-(6-amino-2-butoxi-8-oxo-7,8-dihidro-9h-purin-9-il)propil](3-morfolin-4-ilpropil)amino]metil}fenil)acetato de metilo |
| WO2009091032A1 (ja) | 2008-01-17 | 2009-07-23 | Dainippon Sumitomo Pharma Co., Ltd. | アデニン化合物の製造方法 |
| JPWO2009091031A1 (ja) * | 2008-01-17 | 2011-05-26 | 大日本住友製薬株式会社 | アデニン化合物の製造方法 |
| US9483755B2 (en) | 2008-03-04 | 2016-11-01 | Apple Inc. | Portable multifunction device, method, and graphical user interface for an email client |
| US20090264443A1 (en) * | 2008-04-18 | 2009-10-22 | David Helton | Treatment of organophosphate exposure with tetrahydroindolone arylpiperazine compounds |
| SG157299A1 (en) | 2008-05-09 | 2009-12-29 | Agency Science Tech & Res | Diagnosis and treatment of kawasaki disease |
| EP2331047A4 (de) | 2008-08-29 | 2013-10-30 | Schulman A Inc | Optimierte aromatisierte polymerzusammensetzungen |
| JP2013512859A (ja) * | 2009-12-03 | 2013-04-18 | 大日本住友製薬株式会社 | トール様受容体（ｔｌｒ）を介して作用するイミダゾキノリン |
| US11214610B2 (en) | 2010-12-01 | 2022-01-04 | H. Lundbeck A/S | High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris |
| US9884909B2 (en) | 2010-12-01 | 2018-02-06 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
| EP2646468B1 (de) | 2010-12-01 | 2018-07-25 | AlderBio Holdings LLC | Anti-ngf-zusammensetzungen und ihre verwendung |
| US9539324B2 (en) | 2010-12-01 | 2017-01-10 | Alderbio Holdings, Llc | Methods of preventing inflammation and treating pain using anti-NGF compositions |
| US9067988B2 (en) | 2010-12-01 | 2015-06-30 | Alderbio Holdings Llc | Methods of preventing or treating pain using anti-NGF antibodies |
| US9078878B2 (en) | 2010-12-01 | 2015-07-14 | Alderbio Holdings Llc | Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75 |
| CN103370317B (zh) | 2010-12-16 | 2015-10-07 | 阿斯利康(瑞典)有限公司 | 可用于治疗的咪唑并[4,5-c]喹啉-1-基衍生物 |
| ES2627433T3 (es) | 2010-12-17 | 2017-07-28 | Sumitomo Dainippon Pharma Co., Ltd. | Derivados de purina |
| EP2909314B1 (de) * | 2012-10-19 | 2020-12-02 | Celularity, Inc. | Schmerzbehandlung mit adhärenten zellen aus amnion |
| WO2015058141A1 (en) * | 2013-10-18 | 2015-04-23 | Virginia Tech Intellectual Properties, Inc. | Nucleobase-containing monomers and copolymers |
| US9898162B2 (en) | 2014-05-30 | 2018-02-20 | Apple Inc. | Swiping functions for messaging applications |
| TWI676127B (zh) | 2014-09-02 | 2019-11-01 | 美商蘋果公司 | 關於電子郵件使用者介面之方法、系統、電子器件及電腦可讀儲存媒體 |
| CN108473495B (zh) | 2015-11-20 | 2022-04-12 | 福马治疗有限公司 | 作为泛素-特异性蛋白酶1抑制剂的嘌呤酮 |
| WO2023055531A1 (en) * | 2021-09-28 | 2023-04-06 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Methods for treating peripheral neuropathy |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3300380A (en) | 1963-12-26 | 1967-01-24 | Upjohn Co | Diminishing toxicity of antiviral nu6-(hydroxyalkyl) adenines with 4-hydroxypyrazolo(3, 4-d) pyrimidine |
| US3321369A (en) | 1965-05-26 | 1967-05-23 | Abbott Lab | Method of enhancing learning rate and retention level in warm blooded animals |
| US3438968A (en) | 1966-06-23 | 1969-04-15 | Int Chem & Nuclear Corp | Substituted ammonium basic addition salts of ribonucleic acid |
| BE759011A (fr) | 1969-11-17 | 1971-05-17 | Wellcome Found | Aminopurines |
| DE2554453A1 (de) | 1974-12-18 | 1976-06-24 | Experimentales Et Cliniques De | Medikament zur glykaemieregulierung |
| GB1530912A (en) | 1975-02-13 | 1978-11-01 | Wellcome Found | Compositions containing 9-(2-hydroxy-3-alkyl)-adenines |
| US4138562A (en) | 1977-02-09 | 1979-02-06 | The Regents Of The University Of Minnesota | Adenosine deaminase resistant antiviral purine nucleosides and method of preparation |
| US4221910A (en) | 1978-09-15 | 1980-09-09 | Newport Pharmaceuticals International, Inc. | 9-(Hydroxy alkyl)purines |
| US4221909A (en) | 1978-09-15 | 1980-09-09 | Sloan-Kettering Institute For Cancer Research | P-Acetamidobenzoic acid salts of 9-(hydroxyalkyl) purines |
| US4221794A (en) | 1979-06-21 | 1980-09-09 | Newport Pharmaceuticals International, Inc. | Method of imparting immunomodulating and antiviral activity |
| US4340726A (en) | 1980-03-14 | 1982-07-20 | Newport Pharmaceuticals International, Inc. | Esters |
| US4347360A (en) | 1980-09-16 | 1982-08-31 | Ens Bio Logicals Inc. | Ring open nucleoside analogues |
| US4451478A (en) | 1982-03-12 | 1984-05-29 | Newport Pharmaceuticals International, Inc. | Imidazole compounds |
| US4643992A (en) | 1982-11-09 | 1987-02-17 | Scripps Clinic And Research Foundation | Modulation of animal cellular responses with compositions containing 8-substituted guanine derivatives |
| US5093318A (en) | 1983-11-01 | 1992-03-03 | Scripps Clinic And Research Foundation | Immunostimulating guanosine derivatives and their pharmaceutical compositions |
| US4952693A (en) | 1984-10-12 | 1990-08-28 | Warner-Lambert Company | Oxazolo-pyrimidine derivatives |
| JPH0696534B2 (ja) | 1986-04-25 | 1994-11-30 | ヘキストジヤパン株式会社 | 抗痴呆剤 |
| US5495010A (en) | 1987-04-17 | 1996-02-27 | The United States Of America As Represented By The Department Of Health And Human Services | Acid stable purine dideoxynucleosides |
| EP0338169B1 (de) | 1988-04-19 | 1996-07-24 | Institut Pasteur | Verfahren zur Gewinnung von Schutzantigenen gegen Bordetella-Infektionen und toxische Prozesse |
| US5256677A (en) | 1989-05-23 | 1993-10-26 | Abbott Laboratories | Retroviral protease inhibiting compounds |
| US5187162A (en) | 1989-09-15 | 1993-02-16 | Gensia Pharmaceuticals | Methods of treating neurodegenerative conditions |
| US5026687A (en) | 1990-01-03 | 1991-06-25 | The United States Of America As Represented By The Department Of Health And Human Services | Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds |
| US5091432A (en) * | 1990-03-28 | 1992-02-25 | Glasky Alvin J | 9-substituted hypoxanthine bi-functional compounds and their neuroimmunological methods of use |
| US5237051A (en) | 1990-12-06 | 1993-08-17 | Vanderbilt University | Purified enterotoxin receptor protein |
| US5646155A (en) * | 1994-05-12 | 1997-07-08 | University Of Massachusetts Medical Center | Drugs to prevent recurrent herpes virus infections |
| US5801184A (en) | 1994-07-25 | 1998-09-01 | Glasky; Alvin J. | Carbon monoxide dependent guanylyl cyclase modifiers and methods of use |
| WO1996003125A1 (en) * | 1994-07-25 | 1996-02-08 | Glasky Alvin J | Carbon monoxide dependent guanylyl cyclase modifiers |
| US5447939A (en) * | 1994-07-25 | 1995-09-05 | Glasky; Alvin J. | Carbon monoxide dependent guanylyl cyclase modifiers and methods of use |
| US5795756A (en) | 1995-12-11 | 1998-08-18 | Johnson; Roger A. | Method and compounds for the inhibition of adenylyl cyclase |
| US5948771A (en) | 1996-01-31 | 1999-09-07 | The Trustees Of Columbia University In The City Of New York | Method for treating heart failure using tetrapyrroles and metallotetrapyrroles |
| US5801159A (en) | 1996-02-23 | 1998-09-01 | Galileo Laboratories, Inc. | Method and composition for inhibiting cellular irreversible changes due to stress |
| EP0906090A1 (de) * | 1996-03-15 | 1999-04-07 | Somerset Pharmaceuticals, Inc. | Verfahren zur vorbeugung und behandlung von periphärer neuropathie |
| US6303617B1 (en) | 1998-05-04 | 2001-10-16 | Neotherapeutics, Inc. | Serotonin-like 9-substituted hypoxanthine and methods of use |
| WO1999057119A1 (en) | 1998-05-04 | 1999-11-11 | Neotherapeutics, Inc. | Novel dopamine-like 9-substituted hypoxanthine and methods of use |
| AU3785799A (en) | 1998-05-04 | 1999-11-23 | Neotherapeutics, Inc. | Method for treating migraine in mammals |
| TWI246421B (en) * | 1998-12-03 | 2006-01-01 | Alcon Mfg Ltd | Use of neurotrophic factor stimulators for the treatment of ophthalmic neurodegenerative diseases |
| US6297226B1 (en) * | 1999-10-15 | 2001-10-02 | Neotherapeutics, Inc. | Synthesis and methods of use of 9-substituted guanine derivatives |
-
2001
- 2001-07-06 ES ES01950964T patent/ES2385931T3/es not_active Expired - Lifetime
- 2001-07-06 DE DE60143850T patent/DE60143850D1/de not_active Expired - Lifetime
- 2001-07-06 DK DK01950964.5T patent/DK1334103T3/da active
- 2001-07-06 EP EP01950964A patent/EP1334103B1/de not_active Expired - Lifetime
- 2001-07-06 EP EP07075011A patent/EP1790344B1/de not_active Expired - Lifetime
- 2001-07-06 DE DE60144123T patent/DE60144123D1/de not_active Expired - Lifetime
- 2001-07-06 US US09/899,901 patent/US6630478B2/en not_active Expired - Lifetime
- 2001-07-06 AU AU2001273212A patent/AU2001273212A1/en not_active Abandoned
- 2001-07-06 AU AU2001271908A patent/AU2001271908A1/en not_active Abandoned
- 2001-07-06 WO PCT/US2001/021373 patent/WO2002004448A2/en not_active Ceased
- 2001-07-06 DK DK07075011.2T patent/DK1790344T3/da active
- 2001-07-06 ES ES07075011T patent/ES2420354T3/es not_active Expired - Lifetime
- 2001-07-06 WO PCT/US2001/021526 patent/WO2002004452A2/en not_active Ceased
- 2001-07-06 US US09/900,844 patent/US6630490B2/en not_active Expired - Lifetime
- 2001-07-06 EP EP01952464A patent/EP1334104A2/de not_active Withdrawn
- 2001-07-06 AT AT07075011T patent/ATE499103T1/de active
- 2001-07-06 AT AT01950964T patent/ATE495177T1/de active
Also Published As
| Publication number | Publication date |
|---|---|
| US20020061899A1 (en) | 2002-05-23 |
| EP1790344A3 (de) | 2007-06-27 |
| AU2001271908A1 (en) | 2002-01-21 |
| ATE495177T1 (de) | 2011-01-15 |
| ES2385931T3 (es) | 2012-08-03 |
| WO2002004452A3 (en) | 2003-01-03 |
| US6630490B2 (en) | 2003-10-07 |
| EP1334103B1 (de) | 2011-01-12 |
| ES2420354T3 (es) | 2013-08-23 |
| AU2001273212A1 (en) | 2002-01-21 |
| DK1334103T3 (da) | 2011-04-04 |
| EP1790344A2 (de) | 2007-05-30 |
| WO2002004452A2 (en) | 2002-01-17 |
| HK1102367A1 (en) | 2007-11-16 |
| DK1790344T3 (da) | 2011-05-02 |
| EP1334103A2 (de) | 2003-08-13 |
| DE60144123D1 (de) | 2011-04-07 |
| WO2002004448A2 (en) | 2002-01-17 |
| EP1334104A2 (de) | 2003-08-13 |
| DE60143850D1 (de) | 2011-02-24 |
| WO2002004448A3 (en) | 2003-01-23 |
| US6630478B2 (en) | 2003-10-07 |
| US20020055506A1 (en) | 2002-05-09 |
| EP1790344B1 (de) | 2011-02-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE499103T1 (de) | Verfahren zur behandlung von arzneimittelinduzierter peripherer neuropathie und verwandten krankheitsformen | |
| DE60219793D1 (de) | Methode zur behandlung von zytokinvermittelten erkrankungen | |
| DE602004020263D1 (de) | Amino-substituierte diaryläa,dücyclohepten- analoga als muscarinische agonisten und verfahren zur behandlung von neuropsychiatrischen erkrankungen | |
| ATE396174T1 (de) | Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten | |
| EA200600294A1 (ru) | [1,8] нафтиридин-2-оны и родственные соединения для лечения шизофрении | |
| ATE497778T1 (de) | Lactoferrin-zusammensetzungen und verfahren zur behandlung von diabetischen ulcus | |
| ATE318820T1 (de) | Verfahren zur behandlung von mit p38-kinase assoziierten leiden und pyrrolotriazin- verbindungen als kinaseinhibitoren. | |
| DE602004017736D1 (de) | Verwendung von rapamycin und dessen derivaten zur behandlung von knochenverlust | |
| DE60034871D1 (de) | Verfahren und zusammensetzungen zur prevention oder behandlung von krebs und von krebs assoziertem knochenverlust | |
| DE69941966D1 (de) | Mittel und Verfahren zum Schutz, zur Behandlung und Reparatur von Bindegewebe | |
| ATE432930T1 (de) | Benzosulfonamide derivate, deren verfahren zum herstellung, und deren verwendung zur behandlung von schmerzen | |
| ATE415163T1 (de) | Verfahren und zusammensetzungen zur behandlung von augenerkrankungen | |
| DE60237521D1 (de) | Verfahren zur hemmung der ethylenreaktionen von pflanzen | |
| DE602004023100D1 (de) | Verbindungen und verfahren zur behandlung von dyslipidemie | |
| DE69721824D1 (de) | Verwendung von carbonanhydrase-hemmern zur behandlung von makulär-ödemen | |
| ATE444749T1 (de) | Benzothiazolium verbindungen zur verwendung in methoden zur hemmung der no produktion und von tnf alpha und zur behandlung von coronavirus infektionen | |
| ATE209914T1 (de) | Verwendung von pyridylmethylsulfinyl-1h- benzimidazol derivaten zur behandlung durch helicobacter verursachter erkrankungen | |
| ATE334124T1 (de) | Chinolinderivate, herstellungsprozess und verwendung zur behandlung von krankheiten, bei den s-cd23 involviert ist | |
| DE60124255D1 (de) | Verwendung von exogenen milchsäurebakterien zur behandlung von durch actinomyces naeslundii hervorgerufenen krankheiten | |
| DE60224884D1 (de) | Verfahren zur herstellung von 3, 3', 6, 6'-tetraalkylen-2, 2'-biphenolen und 3, 3', 6, 6'-tetraalkylen-5, 5'-dihalo-2, 2' biphenolen | |
| DE60119671D1 (de) | Verfahren zur Behandlung von Holzwerkstoff | |
| DE602004022864D1 (de) | 4-oxo-4,5-dihydro-furan-2-carbonsäure und derivate und verfahren zur behandlung von stoffwechselerkrankungen mit diesen verbindungen | |
| ATE323715T1 (de) | Verfahren zur inaktivierung von prionen in lipoproteinen | |
| EP1359910A4 (de) | Methode zur behandlung von glaukom ii b | |
| DE60213219D1 (de) | Verwendung von thiolutin dioxide und ihren derivaten zur herstellung eines arzneimittels zur behandlung von zns-krankheiten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1790344 Country of ref document: EP |